The use of desmoteplase (bat saliva) in the treatment of ischaemia

Expert Opinion on Biological Therapy

Volumn 13, Issue 3, 2013, Pages 447-453

  Piechowski Jozwiak, Bartlomiej ^a,b   Bogousslavsky, Julien ^c  

^a Princess Royal University Hospital   (United Kingdom)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c Center for Brain and Nervous System Diseases (Neurocenter)   (Switzerland)

Author keywords

Desmoteplase; Ischaemia; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; DESMOTEPLASE; FIBRIN; PLACEBO; RECOMBINANT ENZYME; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BINDING AFFINITY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CORONARY ARTERY THROMBOSIS; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXCITOTOXICITY; FIBRINOLYTIC THERAPY; HUMAN; LUNG EMBOLISM; MECHANICAL THROMBECTOMY; NEUROTOXICITY; NONHUMAN; RANKIN SCALE; REVIEW; SINGLE DRUG DOSE; STROKE PATIENT;

EXPERT TESTIMONY; FIBRINOLYTIC AGENTS; HUMANS; ISCHEMIA; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS;

EID: 84873913272     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.767327     Document Type: Review

References (42)

1. Ouriel K. A history of thrombolytic therapy. J Endovasc Ther 2004;11(Suppl 2):II128-33
2. Actilyse, Summary of Product Characteristics. Available from: http://www.medicines.org.uk/emc/medicine/308#INDICATIONShttp://www. medicines.org.uk/emc/medicine/308-INDICATIONS
3. Available from: http://www.eso-stroke. org/pdf/ESO-Guideline-Update-Jan- 2009.pdfhttp://www.esostroke.org/pdf/ESO-Guideline-Update-Jan-2009.pdf
4. The National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29
6. Arnold AE, Brower RW, Collen D, et al. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA. J Am Coll Cardiol 1989;14(3):581-8
7. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010;38(3):376-85
8. Dafer RM, Biller J. Desmoteplase in the treatment of acute ischemic stroke. Expert Rev Neurother 2007;7:333-7
9. Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012;165(1):75-89
10. Mazighi M, Meseguer E, Labreuche J, Amarenco P. Bridging therapy in acute ischemic stroke: a systematic review and meta-analysis. Stroke 2012;43(5):1302-8
11. Available from: http://www.ninds.nih. gov/disorders/clinical-trials/ NCT00359424.htm
12. Ciccone A, Valvassori L, Ponzio M, et al. Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv Surg 2010;2(1):74-9
13. Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01062698?term=THRACE&rank= 1http://www.clinicaltrials.gov/ct2/show/ NCT01062698?term=THRACE&rank=1
14. Ma H, Parsons MW, Christensen S, et al. A multicenter, randomized, double-blinded, placebo-controlled Phase III study to investigate Extending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012;7(1):74-80
15. Haley EC Jr, Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41(4):707-11
16. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366(12):1099-107
17. Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis-(ATTEST). Available from: http://clinicaltrials.gov/ct2/show/NCT01472926?term=stroke+ AND+thrombolysis&rank=11
18. A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. Available from: http:// clinicaltrials.gov/ct2/sho/NCT01014975?term=stroke+AND+thrombolysis&rank= 41http://clinicaltrials.gov/ct2/show/NCT01014975?term=stroke+AND +thrombolysis&rank=41
19. Gardell SJ, Duong LT, Diehl RE, et al. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989;264(30):17947-52
20. Gardell SJ, Hare TR, Bergum PW, et al. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 1990;76(12):2560-4
21. Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995;270(43):25596-603
22. Kratzschmar J, Haendler B, Langer G, et al. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus, cloning and expression. Gene 1991;105:229-37
23. Schleuning WD, Alagon A, Boidol W, et al. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann NY Acad Sci 1992;667:395-403
24. Lopez-Atalaya JP, Roussel BD, Ali C, et al. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007;38(3):1036-43
25. Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34(2):537-43
26. Benchenane K, Berezowski V, Fernandez-Monreal M, et al. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 2005;36(5):1065-70
27. Witt W, Maass B, Baldus B, et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalisation by intravenous bolus administration. Circulation 1994;90(1):421-6
28. Witt W, Baldus B, Bringmann P, et al. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992;79(5):1213-17
29. Schleuning WD. Vampire bat plasminogen activator DSPA-Alfa-1 (Desmoteplase): a thrombolytic drug optimized by natural selection. Hemostasis 2001;31:118-22
30. Tebbe U, Bramlage P, Graf A, et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009;101:557-62
31. Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36(1):66-73
32. Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37(5):1227-31
33. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8(2):141-50
34. Soehngen W, Petersen KU, Soehngen M. Bat plasminogen activator: desmoteplase-from bat to bench to bedside of stroke victims. In: Kini RM, editor. Toxins and haemostasis. Springer Science+Business Media B.V; Dordrecht, Heidelberg, London and New York; 2010. p. 393-407
35. Fiebach JB, Al-Rawi Y, Wintermark M, et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012;43(6):1561-6
36. The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379 (9834) 2352-63
37. Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-3). Available from: http://clinicaltrials.gov/ct2/show/NCT00790920/http:// clinicaltrials.gov/ct2/show/NCT00790920/
38. Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4). Available from: http://clinicaltrials.gov/ct2/show/NCT00856661/http:// clinicaltrials.gov/ct2/show/NCT00856661/
39. Available from: http://clinicaltrials.gov/ct2/show/NCT01104467?term=DIAS- J&rank=1
40. Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. Expert Opin Biol Ther 2009;9(6):773-8
41. von Kummer R, Albers GW, Mori E; DIAS Steering Committees. The desmoteplase in acute ischemic stroke (DIAS) clinical trial program. Int J Stroke 2012;7(7):589-96
42. Mishra NK, Albers GW, Davis SM, et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010;41(1):e25-33